Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non-Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations.
Journal: Cancer research
Published: August 07, 2025
ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors.
Journal: Cancer research communications
Published: February 23, 2024
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 10, 2023
Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer.
Journal: JCO precision oncology
Published: November 01, 2018
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.
Journal: Cancer discovery
Published: July 27, 2018
Response to Entrectinib in Differentiated Thyroid Cancer With a ROS1 Fusion.
Journal: JCO precision oncology
Published: December 08, 2017
Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 03, 2017
ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms.
Journal: Molecular cancer therapeutics
Published: May 22, 2017
Activity of Entrectinib in a Patient With the First Reported NTRK Fusion in Neuroendocrine Cancer.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: May 11, 2017
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Journal: Cancer discovery
Published: November 03, 2016
Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor.
Journal: NPJ precision oncology
Published: October 06, 2016
Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 29, 2016
Last Updated: 09/26/2026